References
- Cella DF, Tulsky DS Quality of life in cancer: definition, purpose, and method of measurement. Cancer Invest. 1993;11(3):327–336.
- Wagner M, Wiig H Tumor interstitial fluid formation, characterization, and clinical implications. Front Oncol. 2015;5:115.
- Chaplain M, Sleeman B Modelling the growth of solid tumours and incorporating a method for their classification using nonlinear elasticity theory. J Math Biol. 1993;31(5):431–473.
- Ramaekers F, Puts J, Kant A, et al. Differential diagnosis of human carcinomas, sarcomas and their metastases using antibodies to intermediate-sized filaments. Eur J Cancer Clin Oncol. 1982;18(12):1251–1257.
- Osborne C, Wilson P, Tripathy D Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist. 2004;9(4):361–377.
- Omar A, Reusch U, Knackmuss S, et al. Anti-LRP/LR-specific antibody IgG1-iS18 significantly reduces adhesion and invasion of metastatic lung, cervix, colon and prostate cancer cells. J Mol Biol. 2012;419(1):102–109.
- Anand P, Kunnumakara AB, Sundaram C, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097–2116.
- Likes WM, Itano J Human papillomavirus and cervical cancer: not just a sexually transmitted disease. J Clin J Oncol Nurs. 2003;7(3):271–276.
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- Bray F. Transitions in human development and the global cancer burden. In: Wild CP, Lyon BA Stewart, editors. World cancer report. France: International Agency for Research on Cancer; 2014. p. 54–68.
- Cancer prevention and control in the context of an integrated approach [Internet]. Geneva, Switzerland. 2017. [cited 2019 Aug 20]. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA70/A70_32-en.pdf
- Omran AR The epidemiologic transition: a theory of the epidemiology of population change. Milbank Q. 2005;83(4):731–757.
- Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609–e616.
- Morhason-Bello IO, Odedina F, Rebbeck TR, et al. Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. Lancet Oncol. 2013;14(4):e142–e151.
- Parkin DM, Bray F, Ferlay J, et al. Cancer in africa 2012. Cancer Epidemiol Prev Biomarkers. 2014;23(6):953–966.
- South African National Cancer Registry. National Cancer Registry: Cancer in South Africa 2014 [Internet]. 2018. [cited 2019 Aug 20]. Available from: www.ncr.ac.za
- Takimoto CH, Calvo E Principles of oncologic pharmacotherapy. Cancer Manage. 2008;11:1–9.
- Wender RC, Brawley OW, Fedewa SA, et al. A blueprint for cancer screening and early detection: advancing screening’s contribution to cancer control. CA Cancer J Clin. 2019;69(1):50–79.
- Nagpal M, Singh S, Singh P, et al. Tumor markers: A diagnostic tool. Natl J Maxillofac Surg. 2016;7(1):17.
- Seyfried TN, Huysentruyt LC On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1–2):43
- Hanahan D, Weinberg RA The hallmarks of cancer. cell. 2000;100(1):57–70.
- DiGiacomo V, Meruelo D Looking into laminin receptor: critical discussion regarding the non‐integrin 37/67‐kDa laminin receptor/RPSA protein. Biol Rev. 2016;91(2):288–310.
- Zidane N, Ould-Abeih MB, Petit-Topin I, et al. The folded and disordered domains of human ribosomal protein SA have both idiosyncratic and shared functions as membrane receptors. Biosci Rep. 2013;33(1):e00011.
- Ardini E, Pesole G, Tagliabue E, et al. The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution. Mol Biol Evol. 1998;15(8):1017–1025.
- Jaseja M, Mergen L, Gillette K, et al. Structure–function studies of the functional and binding epitope of the human 37 kDa laminin receptor precursor protein. J Pept Res. 2005;66(1):9–18.
- Jamieson KV, Hubbard SR, Meruelo D Structure-guided identification of a laminin binding site on the laminin receptor precursor. J Mol Biol. 2011;405(1):24–32.
- Jamieson KV, Wu J, Hubbard SR, et al. Crystal structure of the human laminin receptor precursor. J Biol Chem. 2008;283(6):3002–3005.
- O’Donohue M-F, Choesmel V, Faubladier M, et al. Functional dichotomy of ribosomal proteins during the synthesis of mammalian 40S ribosomal subunits. J Cell Biol. 2010;190(5):853–866.
- Landowski TH, Dratz E, Starkey J Studies of the structure of the metastasis-associated 67 kDa laminin binding protein: fatty acid acylation and evidence supporting dimerization of the 32 kDa gene product to form the mature protein. Biochemistry. 1995;34(35):11276–11287.
- Kinoshita K, Kaneda Y, Sato M, et al. LBP-p40 binds DNA tightly through associations with histones H2A, H2B, and H4. Biochem Biophys Res Commun. 1998;253(2):277–282.
- Venticinque L, Meruelo D Comprehensive proteomic analysis of nonintegrin laminin receptor interacting proteins. J Proteome Res. 2012;11(10):4863–4872.
- Venticinque L, Jamieson KV, Meruelo D Interactions between laminin receptor and the cytoskeleton during translation and cell motility. PloS One. 2011;6(1):e15895.
- Ludwig GV, Kondig JP, Smith JF A putative receptor for Venezuelan equine encephalitis virus from mosquito cells. J Virol. 1996;70(8):5592–5599.
- Tio PH, Jong WW, Cardosa MJ Two dimensional VOPBA reveals laminin receptor (LAMR1) interaction with dengue virus serotypes 1, 2 and 3. Virol J. 2005;2(1):25.
- Rieger R, Edenhofer F, Lasmézas CI, et al. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med. 1997;3(12):1383.
- Gauczynski S, Peyrin JM, Haïk S, et al. The 37‐kDa/67‐kDa laminin receptor acts as the cell‐surface receptor for the cellular prion protein. Embo J. 2001;20(21):5863–5875.
- Gauczynski S, Nikles D, El-Gogo S, et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis. 2006;194(5):702–709.
- Kim KJ, Chung JW, Kim KS 67-kDa laminin receptor promotes internalization of cytotoxic necrotizing factor 1-expressing Escherichia coli K1 into human brain microvascular endothelial cells. J Biol Chem. 2005;280(2):1360–1368.
- Jovanovic K, Chetty CJ, Khumalo T, et al. Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer’s disease. Expert Opin Ther Pat. 2015;25(5):567–582.
- Otgaar TC, Ferreira E, Malindisa S, et al. 37 kDa LRP:: FLAG enhances telomerase activity and reduces senescent markers in vitro. Oncotarget. 2017;8(49):86646.
- Zuber C, Knackmuss S, Zemora G, et al. Invasion of tumorigenic HT1080 cells is impeded by blocking or downregulating the 37-kDa/67-kDa laminin receptor. J Mol Biol. 2008;378(3):530–539.
- Chetty C, Khumalo T, Da Costa Dias B, et al. Anti-LRP/LR specific antibody IgG1-iS18 impedes adhesion and invasion of liver cancer cells [Research support, Non-U.S. Gov’t]. PLoS One. 2014;9(5):e96268. PubMed PMID: 24798101; PubMed Central PMCID: PMC4010454. eng.
- Khumalo T, Reusch U, Knackmuss S, et al. Adhesion and invasion of breast and oesophageal cancer cells are impeded by anti-LRP/LR-specific antibody IgG1-iS18. PLoS One. 2013;8(6):p.e66297.
- Vania L, Chetty CJ, Ferreira E, et al. anti-LRP/LR–specific antibody igG1-iS18 significantly impedes adhesion and invasion in early-and late-stage colorectal carcinoma cells. Mol Med. 2016;22:664.
- Rebelo TM, Chetty CJ, Ferreira E, et al. Anti-LRP/LR-specific antibody IgG1-iS18 impedes adhesion and invasion of pancreatic cancer and neuroblastoma cells. BMC Cancer. 2016;16(1):917.
- Munien C, Rebelo TM, Ferreira E, et al. IgG1-iS18 impedes the adhesive and invasive potential of early and late stage malignant melanoma cells. Exp Cell Res. 2017;351(2):135–141.
- Thepparit C, Smith DR Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J Virol. 2004;78(22):12647–12656.
- Dias BDC, Jovanovic K, Gonsalves D, et al. Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs rescue cells from Aβ42 induced cytotoxicity. Sci Rep. 2013;3:2702.
- Jovanovic K, Gonsalves D, Dias BDC, et al. Anti-LRP/LR specific antibodies and shRNAs impede amyloid beta shedding in Alzheimer’s disease. Sci Rep. 2013;3:2699.
- Pinnock EC, Jovanovic K, Pinto MG, et al. LRP/LR antibody mediated rescuing of amyloid-β-induced cytotoxicity is dependent on PrPc in Alzheimer’s disease. J Alzheimers Dis. 2016;49(3):645–657.
- Khusal R, Dias BDC, Moodley K, et al. In vitro inhibition of angiogenesis by antibodies directed against the 37kDa/67kDa laminin receptor. PloS One. 2013;8(3):e58888.
- Rebelo TM, Vania L, Ferreira E, et al. siRNA-mediated LRP/LR knock-down reduces cellular viability of malignant melanoma cells through the activation of apoptotic caspases. Exp Cell Res. 2018;368(1):1–12.
- Chetty CJ, Ferreira E, Jovanovic K, et al. Knockdown of LRP/LR induces apoptosis in pancreatic cancer and neuroblastoma cells through activation of caspases. Exp Cell Res. 2017;360(2):264–272.
- Khumalo T, Ferreira E, Jovanovic K, et al. Knockdown of LRP/LR induces apoptosis in breast and oesophageal cancer cells. PloS One. 2015;10(10):e0139584.
- Vania L, Rebelo TM, Ferreira E, et al. Knock-down of LRP/LR promotes apoptosis in early and late stage colorectal carcinoma cells via caspase activation. BMC Cancer. 2018;18(1):602.
- Coggin JJ, Barsoum A, Rohrer J 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers. Anticancer Res. 1999;19(6C):5535–5542.
- Barsoum AL, Liu B, Rohrer JW, et al. Production, safety and antitumor efficacy of recombinant Oncofetal Antigen/immature laminin receptor protein. Biomaterials. 2009;30(17):3091–3099.
- Biragyn A, Schiavo R, Olkhanud P, et al. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity. J Immunol. 2007;179(2):1381–1388.
- Pelosi G, Pasini F, Bresaola E, et al. High‐affinity monomeric 67‐kd laminin receptors and prognosis in pancreatic endocrine tumours. J Pathol. 1997;183(1):62–69.
- Givant-Horwitz V, Davidson B, Reich R Laminin-induced signaling in tumor cells. Cancer Res. 2004;64(10):3572–3579.
- Nelson J, McFerran NV, Pivato G, et al. The 67 kDa laminin receptor: structure, function and role in disease. Biosci Rep. 2008;28(1):33–48.
- Fatehullah A, Doherty C, Pivato G, et al. Interactions of the 67 kDa laminin receptor and its precursor with laminin. Biosci Rep. 2010;30(2):73–79.
- Chetty C, Khumalo T, Dias BDC, et al. Anti-LRP/LR specific antibody IgG1-iS18 impedes adhesion and invasion of liver cancer cells. PloS One. 2014;9(5):e96268.
- Ménard S, Castronovo V, Tagliabue E, et al. New insights into the metastasis‐associated 67 kD laminin receptor. J Cell Biochem. 1997;67(2):155–165.
- Carmeliet P, Jain RK Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249.
- Tonnesen MG, Feng X, Clark RA Angiogenesis in wound healing. J Invest Dermatol Symp Proc. 2000;5(1):40–46.
- Benazzi C, Al-Dissi A, Chau C, et al. Angiogenesis in spontaneous tumors and implications for comparative tumor biology. Sci World J. 2014;2014:919570.
- Selleri C, Ragno P, Ricci P, et al. The metastasis-associated 67-kDa laminin receptor is involved in G-CSF–induced hematopoietic stem cell mobilization. Blood. 2006;108(7):2476–2484.
- Elmore S Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.
- Naidoo K, Malindisa ST, Otgaar TC, et al. Knock-down of the 37kDa/67kDa laminin receptor LRP/LR impedes telomerase activity. PloS One. 2015;10(11):e0141618.
- Salama RH, Muramatsu H, Zou K, et al. Midkine binds to 37-kDa laminin binding protein precursor, leading to nuclear transport of the complex. Exp Cell Res. 2001;270(1):13–20.
- Tsutsui J-I, Kadomatsu K, Matsubara S, et al. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms’ tumor and other human carcinomas. Cancer Res. 1993;53(6):1281–1285.
- Shi Y Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9(3):459–470.
- Lu C-L, Xu J, Yao H-J, et al. Inhibition of human 67-kDa laminin receptor sensitizes multidrug resistance colon cancer cell line SW480 for apoptosis induction. Tumor Biol. 2016;37(1):1319–1325.
- Sun L, Liu L, Liu X, et al. MGr1‐Ag/37LRP induces cell adhesion‐mediated drug resistance through FAK/PI3K and MAPK pathway in gastric cancer. Cancer Sci. 2014;105(6):651–659.
- Plati J, Bucur O, Khosravi-Far R Apoptotic cell signaling in cancer progression and therapy. Integr Biol. 2011;3(4):279–296.
- Roy S, Nicholson DW Cross-talk in cell death signaling. J Exp Med. 2000;192(8):F21–F26.
- Huerta S, Goulet EJ, Livingston EH Colon cancer and apoptosis. Am J Surg. 2006;191(4):517–526.
- Hotchkiss RS, Nicholson DW Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6(11):813.
- Blackburn EH Structure and function of telomeres. Nature. 1991;350(6319):569.
- Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. cell. 1999;97(4):503–514.
- Olovnikov AM A theory of marginotomy: the incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol. 1973;41(1):181–190.
- Von Zglinicki T, Saretzki G, Ladhoff J, et al. Human cell senescence as a DNA damage response. Mech Ageing Dev. 2005;126(1):111–117.
- Wright WE, Shay JW The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol. 1992;27(4):383–389.
- Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656.
- Finkel T, Serrano M, Blasco MA The common biology of cancer and ageing. Nature. 2007;448(7155):767.
- Shay JW, Wright WE Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis. 2004;26(5):867–874.
- Herbert B-S, Pitts A, Baker S, et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Nat Acad Sci. 1999;96(25):14276–14281.
- Lee J, Sung Y, Cheong C, et al. TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene. 2008;27(26):3754.
- Gorbunova V, Seluanov A, Pereira-Smith OM Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis. J Biol Chem. 2002;277(41):38540–38549.
- Massard C, Zermati Y, Pauleau A-L, et al. hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene. 2006;25(33):4505.
- Shay J, Bacchetti S A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33(5):787–791.
- Cerone MA, Londoño-Vallejo JA, Autexier C Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol Cancer Ther. 2006;5(7):1669–1675.
- Filaci G, Indiveri F. Anti-tumor immunotherapy WO/2010/003520A2. 2010 [cited 2019 Jul 25]. Available from: https://patentsgooglecom/patent/WO2010003520A2/en?q=cancer&q=telomerase&oq=cancer+and+telomerase
- Gryaznov S, Pongracz K. Modified oligonucleotides for telomerase inhibition WO/2005/023994A2. 2005 [cited 2019 Jul 25]. Available from: https://patentsgooglecom/patent/WO2005023994A2/en?q=cancer&q=telomerase&oq=cancer+and+telomerase&page=1
- Kwon YA, Choi WC, Jun HJ, et al. Method for inhibiting telomerase in cancer cells by means of luterion WO/2016/111530A1. 2016 [cited 2019 Jul 25]. Available from: https://patentsgooglecom/patent/WO2016111530A1/en?q=cancer&q=telomerase&oq=cancer+and+telomerase&page=1
- Shay JW, Gryaznov SM. Telomerase mediated telomere altering compounds WO/2014/168947A2. 2014 cited 2019 Jul 25. Available from: https://patentsgooglecom/patent/WO2014168947A2/en?q=cancer&q=telomerase&before=priority:20190101&after=priority:20100101
- Moore MAS, Chin AC. Cancer treatment by combined inhibition of proteasome and telomerase activities WO/2006/113470A2. 2006 [cited 2019 Jul 25]. Available from: https://patentsgooglecom/patent/WO2006113470A2/en?q=cancer&q=telomerase&oq=cancer+and+telomerase
- Singh BN, Shankar S, Srivastava RK Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011;82(12):1807–1821.
- Naasani I, Oh-hashi F, Oh-hara T, et al. Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res. 2003;63(4):824–830.
- Weiss SFT, Letsolo BT, Naidoo K, et al. Compunds for the use in the treatment of telomere related diseases and/or telomere related medical conditions WO/2017/077516A3. 2017 [cited 2019 Jul 25]. Available from: http://wwwfreepatentsonlinecom/ASN-UNIVERSITY+OF+THE+WITWATERSRANDhtml
- Bignoux MJ, Cuttler K, Otgaar TC, et al. LRP:: FLAG rescues cells from amyloid-β-mediated cytotoxicity through increased TERT levels and telomerase activity. J Alzheimers Dis. 2019 ( Preprint):69(3):729–741.
- Saretzki G Extra-telomeric functions of human telomerase: cancer, mitochondria and oxidative stress. Curr Pharm Des. 2014;20(41):6386–6403.
- Modugno M, Tagliabue E, Ardini E, et al. p53-dependent downregulation of metastasis-associated laminin receptor. Oncogene. 2002;21(49):7478.
- Rahman R, Latonen L, Wiman KG hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene. 2005;24(8):1320.
- Xu D, Wang Q, Gruber A, et al. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene. 2000;19(45):5123.
- Maida Y, Kyo S, Kanaya T, et al. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene. 2002;21(26):4071.
- Duan S-G, Cheng L, Li D-J, et al. The role of MAPK-ERK pathway in 67-kDa laminin receptor-induced FasL expression in human cholangiocarcinoma cells. Dig Dis Sci. 2010;55(10):2844–2852.
- Lavanya V, Mohamed Adil A, Neesar A, et al. Small molecule inhibitors as emerging cancer therapeutics. Integr Cancer Sci Ther. 2014;1(3):39–46.
- Zhang H, Chen J Current status and future directions of cancer immunotherapy. J Cancer. 2018;9(10):1773.
- Sawyers C Targeted cancer therapy. Nature. 2004;432(7015):294.
- Zhang X, Huang G Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery. Drug Deliv 2017;24(2):16–21.
- Huang G, Huang H Hyaluronic acid-based biopharmaceutical delivery and tumor-targeted drug delivery system. J Control Release 2018;278:122–126.
- Huang G, Liu Y, Chen L Chitosan and its derivatives as vehicles for drug delivery. Drug Deliv 2017;24(2):108–113.
- Chen F, Huang G Application of glycosylation in targeted drug delivery. Eur J Med Chem 2019;182:111612.
- Stewart-Ornstein J, Lahav G Dynamics of CDKN1A in single cells defined by an endogenous fluorescent tagging toolkit. Cell Rep. 2016;14(7):1800–1811.
- Wang Z, Fukuda S, Pelus LM Survivin regulates the p53 tumor suppressor gene family. Oncogene. 2004;23(49):8146.
- Vaziri SA, Grabowski DR, Hill J, et al. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent. Anticancer Res. 2009;29(8):2961–2969.
- Konopleva M, Watt J, Contractor R, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008;68(9):3413–3420.
- Xiong H, Pradhan RS, Nada A, et al. Studying navitoclax, a targeted anticancer drug, in healthy volunteers–ethical considerations and risk/benefit assessments and management. Anticancer Res. 2014;34(7):3739–3746.
- Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–3428.
- Raymond E, Faivre S, Armand JP Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60(1):15–23.
- Kataria BC, Mehta DS, Chhaiya SB Approval of antineoplastic agents in India: comparison with the US and EU regions. Int J Basic & Clin Pharmacol. 2017;1(1):13–21.
- Sardet C, Arnould S, Rodier G DHODH inhibitor and CHK1 inhibitor for treating cancer WO2019012030. 2018 [cited 2019 Jan 17]. Available from: https://patentscopewipoint/search/en/detailjsf?docId=WO2019012030&tab=PCTDESCRIPTION&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=cancer+therapeutics+AND+small+molecule+inhibitors+&recNum=20&maxRec=341751
- Lang L FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology. 2008;134(2):379.
- Lugowska I, Koseła-Paterczyk H, Kozak K, et al. Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther. 2015;8:2251.
- Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31(4):482.
- Arnould S, Rodier G, Matar G, et al. Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition. Oncotarget. 2017;8(56):95206.
- Pesapane A, Di Giovanni C, Rossi FW, et al. Discovery of new small molecules inhibiting 67 kDa laminin receptor interaction with laminin and cancer cell invasion. Oncotarget. 2015;6(20):18116.
- Kim DG, Lee JY, Kwon NH, et al. Chemical inhibition of prometastatic lysyl-tRNA synthetase–laminin receptor interaction. Nat Chem Biol. 2014;10(1):29.
- Tachibana H, Koga K, Fujimura Y, et al. A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol. 2004;11(4):380.
- Johnson J, Bailey H, Mukhtar H Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine. 2010;17(1):3–13.
- Fujimura Y, Sumida M, Sugihara K, et al. Green tea polyphenol EGCG sensing motif on the 67-kDa laminin receptor. PLoS One 2012;7(5):e37942.
- H-n Y, Zhang L-C, Yang J-G, et al. Effect of laminin tyrosine–isoleucine–glycine–serine–arginine peptide on the growth of human prostate cancer (PC-3) cells in vitro. 2009; 616 (1–3): 251–255. Eur J Pharmacol
- Jang J-Y, Lee J-K, Jeon Y-K, et al. Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization. BMC Cancer. 2013;13(1):421.
- Zhou L, Yang F, Li G, et al. Coptisine induces apoptosis in human hepatoma cells through activating 67-kDa laminin receptor/cGMP signaling. Front Pharmacol. 2018;9:517.
- Wei Y, Fan T, Yu M Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin (Shanghai). 2008;40(4):278–288.
- Singh A, Trivedi P, Jain NK Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol. 2018;46(2):274–283.
- Aleku M, Schulz P, Keil O, et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 2008;68(23):9788–9798.
- Schultheis B, Strumberg D, Santel A, et al. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol. 2014;32(36):4141–4148.
- Wang J, Mi P, Lin G, et al. Imaging-guided delivery of RNAi for anticancer treatment. Adv Drug Deliv Rev. 2016;104:44–60.
- Zhang C, Zeng K, Chen X, et al. New precursor miRNA and applications in tumour therapy thereof WO/2016/177343 2016 [cited 2018 Jan 18]. Available from: https://patentscopewipoint/search/en/detailjsf?docId=WO2016177343&tab=PCTBIBLIO&maxRec=1000
- Moodley K, Weiss SF Downregulation of the non-integrin laminin receptor reduces cellular viability by inducing apoptosis in lung and cervical cancer cells. PloS One. 2013;8(3):e57409.
- Weiss SFT, Jovanovic K, Gonsalves D, et al. inventors; University of theWitwatersrand, assignee. Compounds for use in the treatment of Alzheimer’s Disease WO042053A2. 2013.
- Scheiman J, Tseng J-C, Zheng Y, et al. Multiple functions of the 37/67-kd laminin receptor make it a suitable target for novel cancer gene therapy. Mol Ther. 2010;18(1):63–74.
- Meruelo D. Tumor therapy with aphavirus-based and high affinity laminin receptor-targeted vectors WO/2002/076468. 2002 [cited 2019 Jun 13]. Available from: https://patentscopewipoint/search/en/detailjsf?docId=WO2002076468&recNum=7&office=&queryString=FP%3A%28Tumor+therapy+with+high+affinity+laminin+receptor-targeted+vectors%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=8
- Su Z, Yang Z, Xu Y, et al. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. 2015;14(1):48.
- Maverakis E, Cornelius LA, Bowen GM, et al. Metastatic melanoma–a review of current and future treatment options. Acta Derm Venereol. 2015;95(5):516–527.
- Boross P, Leusen JH Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2(6):676.
- Cerny T, Borisch B, Introna M, et al. Mechanism of action of rituximab. Anticancer Drugs. 2002;13:S3–10.
- van de Donk NWJ, Dhimolea E, editors. Brentuximab vedotin. In: MAbs. Taylor & Francis; 2012;4:458–465.
- Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791.
- Neumann T, Schneidewind L, Thiele T, et al. Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation. J Cancer Res Clin Oncol. 2016;142(5):1091–1097.
- Pivot X, Aulagner G, Blay JY, et al. Challenges in the implementation of trastuzumab biosimilars: an expert panel’s recommendations. Anticancer Drugs. 2015;26(10):1009–1016.
- Frye S, McDonagh C, Moyo V. Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics WO2013170263. 2013 [cited 2019 Jan 17]. Available from: https://patentscopewipoint/search/en/detailjsf?docId=WO2013170263&tab=NATIONALPHASE&maxRec=1000
- Teillaud J-L. From whole monoclonal antibodies to single domain antibodies: think small. In: Saerens D, Muyldermans S, editors. Single domain antibodies. Totowa, NJ: Humana Press; 2012. p. 3–13.
- Chen R, Chen B Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma. Drug Des Devel Ther. 2015;9:1729.
- Vermot-Desroches C, Kong-Flohr C, Godinat M, et al. Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti-CD20 antibodies or chemotherapeutics WO2019011918. 2019 [cited 2019 Jan 17]. Available from: https://patentscopewipoint/search/en/detailjsf?docId=WO2019011918&tab=PCTBIBLIO&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=cancer+therapeutics+AND+patents&recNum=14&maxRec=498616
- Knackmuss S, Rey C, Rottgen P, et al. Single chain antibody acting against 37kDa/67kDa laminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof WO/2005/035580. 2005 [cited 2019 Jun 13]. Available from: https://patentscopewipoint/search/en/detailjsf?docId=WO2005035580
- Findlay HP, Hahn SE, Kelleher M, et al. Cancerous disease modifying antibodies. Google Patents. 2005.
- Little M, Reusch U, Kipriyanov S, et al. Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types WO2006/105954. 2006 [cited 2019 Jun 13]. https://patentscopewipoint/search/en/detailjsf?docId=WO2006105954
- Berman D, Matsui W, He X. 67lr antibodies and their uses in the treatment of cancer patent WO2008/115601A1. 2008 [cited 2019 Nov 7]. Available from: https://wwwlensorg/lens/patent/092-534-674-714-610/fulltext
- Fülöp T, Larbi A, editors. Putative role of 67 kDa elastin-laminin receptor in tumor invasion. In: Seminars in cancer biology. Elsevier; 2002:12(3):219–229.
- Weeks B, DiSalvo J, Kleinman H Laminin‐mediated process formation in neuronal cells involves protein dephosphorylation. J Neurosci Res. 1990;27(3):418–426.
- Liotta LA, Stetler-Stevenson WG Tumor invasion and metastasis: an imbalance of positive and negative regulation. 1991;51(18 Supplement):5054s–5059s. Cancer Res
- Narumi K, Inoue A, Tanaka M, et al. Inhibition of experimental metastasis of human fibrosarcoma cells by anti‐recombinant 37‐kDa laminin binding protein antibody. Jpn J Cancer Res. 1999;90(4):425–431.
- McClintock SD, Warner RL, Ali S, et al. Monoclonal antibodies specific for oncofetal antigen–immature laminin receptor protein: effects on tumor growth and spread in two murine models. Cancer Biol Ther. 2015;16(5):724–732.
- Johnson K, Morgan AC, Varani J, et al. Tumor selective antibodies specific to oncofetal antigen/immature laminin receptor protein WO/2015/017113. 2015 [cited 2019 Jun 13]. Available from: https://patentscopewipoint/search/en/detailjsf?docId=WO2015017113&recNum=3&office=&queryString=FP%3A%28Tumor+selective+antibodies+specific+to+oncofetal+antigen%2Fimmature+laminin+receptor+protein%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=3
- Anguille S, Smits EL, Lion E, et al. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257–e267.
- Rohrer JW, Barsoum AL, Coggin JH Identification of oncofetal antigen/immature laminin receptor protein epitopes that activate BALB/c mouse OFA/iLRP-specific effector and regulatory T cell clones. J Immunol. 2006;176(5):2844–2856.
- Rohrer JW, Coggin JH, Barsoum AL. Vaccines with oncofetal antigen/iLRP-loaded autologous dendritic cells and uses thereof WO/2011/006084. 2011 [cited 2018 Jun 13]. Available from: https://patentscopewipoint/search/en/detailjsf?docId=WO2011006084&recNum=3&office=&queryString=FP%3A%28Vaccines+with+oncofetal+antigen%2Filrp-loaded+autologous+dendritic+cells+and+uses+thereof%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=3
- Coggin J, Rohrer J, Barsoum A. Cancer vaccines containing epitopes of oncofetal antigen WO/2004/012681. 2004 [cited 2019 Jun 13]. Available from: https://patentscopewipoint/search/en/detailjsf?docId=WO2004012681&redirectedID=true
- Siegel S, Wagner A, Friedrichs B, et al. Identification of HLA-A* 0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies. J Immunol. 2006;176(11):6935–6944.
- Siegel S, Wagner A, Kabelitz D, et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood. 2003;102(13):4416–4423.
- Siegel S, Zeis M. OFA/iLRP derived modified peptide. 2011 [cited 2019 Jun 12]. Available from: https://patentsgooglecom/patent/EP2330122A1/en
- Umbaugh CS, Figueiredo ML Lysines residing in putative small Ubiquitin-like MOdifier (SUMO) motifs regulate fate and function of 37 KDa laminin receptor. Biochimie. 2019;156:92–99.
- Zhang S, Zhou Y, Sarkeshik A, et al. Identification of RNF8 as a ubiquitin ligase involved in targeting the p12 subunit of DNA polymerase δ for degradation in response to DNA damage. J Biol Chem. 2013;288(5):2941–2950.
- Tay S-P, Yeo CW, Chai C, et al. Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J Biol Chem. 2010;285(38):29231–29238.
- Cesari R, Martin ES, Calin GA, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27. Proc Nat Acad Sci. 2003;100(10):5956–5961.
- Denison SR, Wang F, Becker NA, et al. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene. 2003;22(51):8370.
- Picchio MC, Martin ES, Cesari R, et al. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res. 2004;10(8):2720–2724.
- Seirafi M, Kozlov G, Gehring K Parkin structure and function. Febs J. 2015;282(11):2076–2088.
- Chan NC, Salazar AM, Pham AH, et al. Broad activation of the ubiquitin–proteasome system by Parkin is critical for mitophagy. Hum Mol Genet. 2011;20(9):1726–1737.
- Mizuno Y, Hattori N, Mori H, et al. Parkin and Parkinson’s disease. Curr Opin Neurol. 2001;14(4):477–482.
- Winklhofer KF Parkin and mitochondrial quality control: toward assembling the puzzle. Trends Cell Biol. 2014;24(6):332–341.
- McLelland GL, Soubannier V, Chen CX, et al. Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. Embo J. 2014;33(4):282–295.
- Vincow ES, Merrihew G, Thomas RE, et al. The PINK1–Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc Nat Acad Sci. 2013;110(16):6400–6405.
- Liu J, Zhang C, Hu W, et al. Parkinson’s disease-associated protein Parkin: an unusual player in cancer. Cancer Commun. 2018;38(1):40.
- Fujiwara M, Marusawa H, Wang H, et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene. 2008;27(46):6002.
- da Silva-camargo CCV, Baldin RKS, Polli NLC, et al. Parkin protein expression and its impact on survival of patients with advanced colorectal cancer. Cancer Biol Med. 2018;15(1):61.
- Song D-G, Kim YS, Jung BC, et al. Parkin induces upregulation of 40S ribosomal protein SA and posttranslational modification of cytokeratins 8 and 18 in human cervical cancer cells. Appl Biochem Biotechnol. 2013;171(7):1630–1638.
- Poulogiannis G, McIntyre RE, Dimitriadi M, et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Nat Acad Sci. 2010;107(34):15145–15150.
- Weiss S, Ferreira E, Cuttler K, et al. Compounds for the use in the treatment of Parkinson’s Disease, South Africa provisional patent application 2018/08025 (unpublished).
- Liu J, Zhang C, Zhao Y, et al. Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. Nat Commun. 2017;8(1):1823.
- Wang H, Liu B, Zhang C, et al. Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule‐dependent mechanism. J Pathol. 2009;218(1):76–85.
- Kampan NC, Madondo MT, McNally OM, et al. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int. 2015;2015:413076.